BDRX
Biodexa Pharmaceuticals Plc
$3.11
-0.64%
$2.0M
No data for this timeframe.
Vol
Market Cap$2.0M
Cap SizeNano Cap
Inst. Holders1 funds
Inst. Value$46.1K
Inst. Activity1 buys / 0 sells
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases1
Recent Activity
May 14, 2026
SEC
Biodexa Pharmaceuticals filed its 6-K on May 14, 2026, announcing its Annual General Meeting (AGM) scheduled for June 17
6-K — Impact 4/10
Mar 31, 2026
SEC
Biodexa Pharmaceuticals Plc has had six registration statements declared effective by the SEC, enabling the company to p
EFFECT — Impact 7/10
Inst.
UBS Group AG — NEW
6,925 shares ($46.1K)
Inst.
UBS Group AG — NEAR_EXIT
1,989 shares ($1.7K)
May 14, 2026
other
Biodexa issues letter to Shareholders
<p>May 14, 2026</p>
Mar 23, 2026
Press
Biodexa Pharmaceuticals has partnered with Tanner Pharma Group to launch a global Early Access Program for its investiga
Impact 4/10
Price Targets
Historical data — last covering-analyst action Feb 2024. No current recommendation available.
$35.66 (Feb 2024)
Current $3.11
Low $35.66
Median $35.66
High $35.66
1 analysts
$35.66
$35.66
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 8, 2024 | Ladenburg Thalmann | INITIATE | Buy |
Latest Reports
NEUTRAL
6-K
4/10
Biodexa Pharmaceuticals filed its 6-K on May 14, 2026, announcing its Annual General Meeting (AGM) scheduled for June 17
May 14, 2026
BEARISH
EFFECT
7/10
Biodexa Pharmaceuticals Plc has had six registration statements declared effective by the SEC, enabling the company to p
Mar 31, 2026
NEUTRAL
Press
4/10
Biodexa Pharmaceuticals has partnered with Tanner Pharma Group to launch a global Early Access Program for its investiga
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| UBS Group AG | $46.1K | NEW |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
1 institutional holders with $46.1K total value (6,925 shares) as of 2025-Q3. Top holders: UBS. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 6,925 | $46.1K | 100.0% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | NEW | — | 6,925 | — | $46.1K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 18,832 | 1,989 | -89.4% | $1.7K | 2025-Q2 |
| UBS Group AG | DOUBLED | 7,047 | 18,832 | +167.2% | $24.9K | 2025-Q1 |
| UBS Group AG | NEW | — | 7,047 | — | $28.5K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
Historical analyst distribution (last covering-analyst action Feb 2024): 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2024. No current recommendation available.
$35.66 mean target (Feb 2024)
$35.66 Low
$35.66 High
| Metric | Value |
|---|---|
| Current Price | $3.11 |
| Target Low | $35.66 |
| Target Mean | $35.66 |
| Target Median | $35.66 |
| Target High | $35.66 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | 100.0% | — | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | 0.0% | — | 1↑ 0↓ | $0.0B | 0.0% | 1 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 8, 2024 | Ladenburg Thalmann | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Dec 1, 2025 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
BDRX — 06:42 MT ~ $0.70
▲ 1
💬 0
⚡ 0.5
May 14, 2026
other
Biodexa issues letter to Shareholders
<p>May 14, 2026</p>
May 5, 2026
short_volume
Short Volume: BDRX — 59.5% short (0.9M / 1.5M)
Short: 905,991 | Exempt: 4,102 | TRF Vol: 1,522,667 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
other
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
<p>April 2, 2026</p>
Apr 2, 2026
short_volume
Short Volume: BDRX — 55.6% short (32.7M / 58.9M)
Short: 32,745,894 | Exempt: 184,255 | TRF Vol: 58,928,323 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
earnings
Preliminary Results for the Year Ended 31 December 2025
<p align="left">March 27, 2026</p>
Mar 23, 2026
contract
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
<p>March 23, 2026</p>
Mar 18, 2026
other
ADR Ratio Change
<p><b>March 18, 2026</b></p>
Mar 9, 2026
other
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
<p>March 9, 2026</p>